Marcain Adrenalin (Bupivacaine Hydrochloride, Epinephrine)

Bupivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of nerve impulses. This inhibition stops pain signals from reaching the brain, resulting in a reversible loss of sensation in the targeted area.

The dose of Marcain Adrenalin is individualized by the prescribing clinician based on factors such as the type of procedure, patient weight, age, comorbidities, and the desired duration of anesthesia. No fixed regimen is provided in product literature.

Safety data for Marcain Adrenalin during pregnancy and lactation are limited. The product should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Marcain Adrenalin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Both Marcain Adrenalin and lidocaine are amide‑type local anesthetics, but bupivacaine (in Marcain Adrenalin) has a longer duration of action and higher potency. The addition of epinephrine further prolongs its effect and reduces systemic absorption, whereas lidocaine typically provides a shorter‑acting block without a vasoconstrictor.

Marcain Adrenalin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations to maintain stability.

The product is administered by a qualified healthcare professional via epidural or infiltration injection. Proper aseptic technique, aspiration before injection, and adherence to recommended maximum dose limits are essential to ensure safety and efficacy.

Serious risks include cardiac arrhythmias, central nervous system seizures, and rare cases of methemoglobinemia. Immediate medical attention is required if patients exhibit signs of cardiovascular instability, seizures, or unexplained cyanosis after administration.

Patients with known hypersensitivity to bupivacaine, other amide local anesthetics, or epinephrine should avoid Marcain Adrenalin. It is also contraindicated in individuals with severe cardiac conduction disorders, uncontrolled hypertension, or those receiving certain antiarrhythmic medications.